What Is Heart Ablation? How It Treats Arrhythmias

Heart ablation is a procedure that destroys small areas of heart tissue responsible for causing abnormal heart rhythms. A thin, flexible tube called a catheter is threaded through a blood vessel, usually in the groin, and guided into the heart. Once positioned at the site where faulty electrical signals originate, the catheter delivers energy to create tiny scars that block those signals from spreading. The term “ablation” itself simply means the removal or destruction of tissue, and in cardiology it refers specifically to targeting the misfiring cells that throw the heart’s rhythm off track.

What Ablation Actually Does Inside the Heart

Your heart beats in a coordinated rhythm because of an electrical system that sends impulses along predictable pathways. When something disrupts those pathways, whether from extra electrical connections you were born with or scar tissue from heart disease, the result is an arrhythmia. The heart may beat too fast, too slow, or in an irregular pattern. Medications can sometimes suppress these abnormal signals, but they do not eliminate the source. Ablation takes a more direct approach: it physically alters or destroys the tiny patches of tissue generating the rogue electrical activity.

The catheter tip is positioned with precision using live X-ray imaging and, increasingly, sophisticated three-dimensional mapping systems that create a detailed digital model of the heart’s interior. These mapping systems can identify the exact spot where abnormal signals originate or the pathways they travel along. In some complex cases, doctors merge pre-procedure MRI scans with real-time electrical maps to pinpoint abnormal tissue even more accurately.¹ Advanced mapping modules also allow doctors to replay the heart’s electrical activation in real time, which is especially useful for arrhythmias that are unstable or hard to sustain long enough to map during the procedure.²

The Different Energy Sources Used

Not all ablation procedures use the same type of energy. The choice depends on where in the heart the problem is, what kind of arrhythmia is being treated, and, in some cases, which structures sit near the target tissue.

Radiofrequency ablation is the longest-established method. It uses high-frequency electrical current delivered through the catheter tip to heat the tissue, creating a small, well-defined scar. This remains the workhorse for many types of arrhythmia and is the technique most electrophysiologists are most experienced with.

Cryoablation takes the opposite approach: instead of heating, it freezes the tissue. A coolant circulates through the catheter tip, dropping the temperature low enough to destroy cells. One advantage is that cryotherapy produces different lesion characteristics compared to radiofrequency energy, with a lower incidence of blood clot formation at the ablation site.³ Cryoablation is commonly used via a balloon catheter for pulmonary vein isolation, a specific type of ablation for atrial fibrillation.

Pulsed field ablation is the newest entrant and works by a fundamentally different mechanism. Instead of using temperature, it delivers ultra-short bursts of electrical energy that punch microscopic holes in cell membranes, a process called electroporation. If the electric field is strong enough, the cells cannot recover and die.⁴ The key advantage is tissue selectivity: heart muscle cells are more susceptible to these electrical fields than nearby structures like the esophagus, blood vessels, or nerves. In first-in-human trials, pulsed field ablation achieved durable pulmonary vein isolation with no cases of esophageal injury, phrenic nerve damage, or pulmonary vein narrowing over a median follow-up of about four months.⁵ This selectivity matters because collateral damage to surrounding structures has long been a concern with heat- and cold-based methods.

Which Heart Conditions Ablation Treats

Ablation is used for a range of rhythm disorders, but the success rates and the stakes involved vary considerably depending on the specific arrhythmia.

Supraventricular Tachycardias

These are fast rhythms originating above the heart’s lower chambers. The most common types treated by ablation include atrioventricular nodal reentrant tachycardia (AVNRT, a short-circuiting loop near the heart’s natural electrical relay station) and accessory pathway-mediated tachycardias (extra electrical connections between the upper and lower chambers, as in Wolff-Parkinson-White syndrome). For these conditions, ablation is often considered a cure rather than just a treatment. In a large multicenter trial of over a thousand patients, ablation was successful in the vast majority, with the highest success rates for the simplest targets and slightly lower rates for accessory pathways, which can be located in trickier positions.⁶ For AVNRT specifically, radiofrequency ablation of the slow pathway eliminated the arrhythmia without disrupting normal heart conduction in one early landmark study, with no recurrences over a follow-up period averaging more than 15 months.⁷

Atrial Fibrillation

Atrial fibrillation, often called AFib, is the most common sustained arrhythmia and the one most frequently targeted by ablation today. The procedure typically involves isolating the pulmonary veins, four blood vessels that drain into the left atrium. Research established that these veins often fire off the rapid electrical bursts that trigger AFib episodes.⁸ By creating a ring of scar tissue around the vein openings, the rogue signals are electrically walled off from the rest of the atrium.

For patients whose AFib has not responded to medications, the evidence clearly favors ablation. A meta-analysis of randomized trials comparing ablation to drug therapy as a first-line treatment found that roughly a third of ablation patients experienced recurrent arrhythmia compared to more than half of those on drugs. Ablation also cut hospitalizations by about two-thirds.⁹ In patients who also have heart failure, the results are even more striking. A randomized trial showed that pulmonary vein isolation produced a higher heart pumping fraction, longer walking distance, and better quality-of-life scores compared to an alternative strategy of ablating the heart’s natural relay node and implanting a pacemaker.¹⁰

Ventricular Tachycardia

Ventricular tachycardia (VT) arises from the heart’s lower, pumping chambers and is a more dangerous arrhythmia. It often occurs in patients who have scar tissue from a prior heart attack or from diseases that damage the heart muscle. Ablation for VT aims to disrupt the electrical pathways threading through and around that scar tissue. While ablation effectively reduces recurrent arrhythmias and painful defibrillator shocks, the overall success rates are more modest compared to supraventricular arrhythmias, with procedural success historically sitting between roughly half and two-thirds of patients.¹¹ ¹²

Pulsed field ablation is now being tested for VT as well. A first-in-human trial using a specialized catheter achieved acute procedural success in over 90% of patients. Clinical VT was inducible in most patients before the procedure but in only one patient afterward, and VT episodes dropped by about 98% compared to baseline over follow-up.¹³ These are very early results, but they suggest the technology could improve outcomes for one of the toughest ablation targets.

What the Risks Look Like

Ablation is generally safe, but it is an invasive procedure inside the heart, so complications do occur. The most commonly cited serious risk is cardiac tamponade, where fluid or blood accumulates around the heart after a puncture. Across large datasets, this happens in fewer than one in a hundred procedures. Stroke or a transient loss of brain function from a clot is rarer still, occurring in under two in a thousand cases.¹⁴

One energy-specific risk worth knowing about is phrenic nerve injury during cryoballoon ablation. The phrenic nerve runs near the right pulmonary veins and controls the diaphragm on that side. Freezing in that area can temporarily paralyze the nerve, which happened in roughly 5 to 7% of patients in large series. In most cases the nerve recovers within the procedure or within days. Persistent injury lasting months is much less common, and permanent damage is rare.¹⁵ Doctors monitor diaphragm movement in real time during the freeze and stop immediately if they see it weaken. This is one reason pulsed field ablation’s tissue selectivity has generated so much interest: early data show it avoids phrenic nerve injury entirely.

Catheter Ablation Versus Surgical Ablation

Most ablations are catheter-based, performed through blood vessels without opening the chest. But a surgical version exists, most commonly a minimally invasive procedure done through small incisions between the ribs. A systematic review found that surgical ablation was associated with higher freedom from AFib at every time point compared to catheter ablation.¹⁶ However, a randomized trial comparing the two approaches directly showed that catheter ablation was not significantly worse than minimally invasive surgical ablation for arrhythmia-free survival, while the surgical group experienced substantially more major complications.¹⁷ In practice, surgical ablation is typically reserved for patients undergoing open-heart surgery for another reason (like valve repair) or those who have failed catheter ablation.

Recovery and the Blanking Period

After the procedure, most people spend one night in the hospital and return to normal activities within a few days to a week. You will likely be told to avoid heavy lifting and strenuous exercise for a short period to let the catheter insertion site heal. Blood thinners are continued for at least several weeks, and sometimes longer, to reduce stroke risk while the ablation lesions mature.

One thing that catches many patients off guard is the “blanking period,” typically defined as the first three months after ablation. During this window, it is common to experience arrhythmia episodes, sometimes even more frequently than before the procedure. Studies report that early arrhythmia recurrences happen in roughly a third to two-thirds of patients.¹⁸ This sounds alarming, but it does not mean the ablation failed. The ablation lesions cause temporary inflammation, swelling, and irritation in the heart tissue. These effects are themselves capable of triggering arrhythmias. The tissue swelling typically resolves within about a month, and the inflammatory response fades over the full three-month period.

The practical consequence is that doctors generally do not judge the procedure’s success until after the blanking period ends, and early recurrences alone are not usually a reason to schedule a repeat procedure. According to one meta-analysis, about 38% of patients who have arrhythmias during the blanking period go on to remain arrhythmia-free long-term.¹⁹ That said, recurrences during the third month are more worrisome than those in the first month; data from the ADVICE trial showed that over 90% of patients who experienced recurrences during month three went on to have late recurrences as well.²⁰

Does Ablation Actually Help People Live Longer?

For supraventricular tachycardias, ablation is essentially curative and the rhythm disorder itself is rarely life-threatening, so the benefit is primarily about eliminating symptoms and avoiding lifelong medication. The question of survival is more relevant for AFib, especially in patients who also have heart failure.

The CABANA trial, the largest randomized trial comparing ablation to drug therapy for AFib, did not find a statistically significant difference in a composite endpoint of death, stroke, bleeding, and cardiac arrest between the two groups over five years.²¹ But that trial included many patients with mild disease and had high rates of patients crossing over from drugs to ablation, which blurred the comparison.

When the focus narrows to AFib patients with heart failure, the picture shifts. A meta-analysis of randomized controlled trials with at least two years of follow-up found that ablation reduced all-cause mortality by about 39% and heart failure hospitalizations by about 40% compared to drug therapy alone.²² Real-world data tell a similar story: in one observational study following patients for a median of about four and a half years, death rates in ablated heart failure patients were less than half those of patients managed with medications alone.²³

Quality of Life After Ablation

Even when the survival data are ambiguous, the quality-of-life improvements are not. Patients consistently report feeling substantially better after ablation. In young adults tracked for up to five years after the procedure, 90% reported improved quality of life at every follow-up point, with far fewer and shorter arrhythmia episodes, fewer emergency room visits, and fewer hospitalizations.²⁴ For patients with persistent AFib, quality-of-life scores continued to improve even beyond the first year, rising from a baseline average of about 54 out of 100 to nearly 88 at three years post-ablation.²⁵ One observation that surprises researchers is that quality of life tends to improve after ablation even in some patients whose arrhythmia technically recurs, possibly because the episodes become shorter, less frequent, or less symptomatic.²⁶

Sedation Versus General Anesthesia

One question that comes up before the procedure is whether you will be put under general anesthesia or kept in a lighter state of sedation. The answer depends on the type of arrhythmia being treated and your doctor’s preference, but the evidence suggests both approaches produce comparable outcomes for most metrics. For AFib ablation, one meta-analysis found that general anesthesia or deep sedation was associated with a modest reduction in AFib recurrence compared to lighter sedation, possibly because catheter contact with the heart tissue is more stable when the patient is completely still.²⁷ A separate meta-analysis focusing specifically on AFib found no significant difference in recurrence of arrhythmias between the two approaches.²⁸

For ventricular arrhythmia ablation, a separate meta-analysis found no significant differences in procedure time, acute success, or complications between sedation and general anesthesia. Sedation did, however, come with less blood-pressure instability during the procedure.²⁹ In practice, many centers now lean toward general anesthesia for complex AFib cases and use sedation more often for simpler supraventricular tachycardias.

Why Weight Loss and Lifestyle Changes Matter

Ablation addresses the electrical problem, but it does not fix the underlying conditions that made the heart susceptible to arrhythmia in the first place. This is especially true for AFib, where obesity, uncontrolled blood pressure, sleep apnea, and heavy alcohol use all increase the chance the arrhythmia will come back even after a technically successful procedure.

Weight loss has the strongest evidence behind it. A dose-response meta-analysis found that each 10% reduction in body weight was associated with roughly half the risk of AFib recurrence after ablation.³⁰ In trials that tested aggressive risk-factor management (weight loss, exercise, blood pressure control, sleep apnea treatment) alongside ablation, freedom from AFib at one year was dramatically higher in the actively managed group compared to controls receiving standard care.³¹ In other words, ablation and lifestyle changes are not competing strategies. They work best together.

What It Costs

Ablation is expensive upfront. In the CABANA trial, ablation-related costs in the first three months averaged about $21,000 more than drug therapy. But that gap narrowed over time, because ablation patients needed fewer hospitalizations, emergency visits, and medication adjustments. Over a lifetime horizon, the cost difference shrank to roughly $15,500, and the procedure yielded a modest gain in quality-adjusted life years. The incremental cost per quality-adjusted life year was about $58,000, which falls below the $100,000 threshold commonly used to gauge whether an intervention provides reasonable value in the United States.³² An earlier economic model reached a strikingly similar number, estimating the cost per quality-adjusted life year at about $59,000, with a 90% probability of being cost-effective at a $100,000 willingness-to-pay threshold.³³ Whether this represents good value depends partly on where you live. An Australian analysis using similar modeling concluded that ablation was not cost-effective from their healthcare system’s perspective, which uses a lower willingness-to-pay benchmark.³⁴